Skip to main content
Clinical Trials/NL-OMON40163
NL-OMON40163
Withdrawn
Not Applicable

Visualization of a VEGF-targeted Near-Infrared Fluorescent Tracer in patients with Familial Adenomatous Polyposis during Fluorescence Endoscopy. A single center pilot intervention study - FAP Fluorescence Endoscopy Study

niversitair Medisch Centrum Groningen0 sites15 target enrollmentStarted: TBDLast updated:

Overview

Phase
Not Applicable
Status
Withdrawn
Enrollment
15

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • \* Patients with genetically or clinically proven Familial Adenomatous Polyposis (Genetically proven: APC\-mutation identified. Clinically proven: more than 100 colorectal polyps at diagnosis). ;\* Age 18 to 70 years. ;\* Written informed consent. ;\* Adequate potential for follow\-up.

Exclusion Criteria

  • \* Medical or psychiatric conditions that compromise the patient\*s ability to give informed consent. ;\* Proctocolectomy.;\* MutYH mutation;\* Concurrent uncontrolled medical conditions. ;\* Pregnant or lactating women. Documentation of a negative pregnancy test must be available for woman of childbearing potential. Woman of childbearing potential are pre\-menopausal women with intact reproductive organs and women less than two years after menopause.
  • \* History of infusion reactions to bevacizumab or other monoclonal antibody therapies.
  • \* Received an investigational drug within 30 days prior to intravenous administration of bevacizumab\-800CW.
  • \* Inadequately controlled hypertension with or without current antihypertensive medications.
  • \* Had within 6 months prior to enrollment: MI, TIA, CVA, pulmonary embolism, uncontrolled CHF, significant liver disease, unstable angina.
  • \* Patients receiving anticoagulant therapy with vitamin K antagonists.
  • \* Patients receiving Class IA (quinidine, procanamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.
  • \* Evidence of QT prolongation on pretreatment ECG (greater than 440 ms in males or greater than 450 ms in females).
  • \* Magnesium, potassium and calcium lower than the lower limit of normal range.

Investigators

Similar Trials